Acute changes in systemic glycaemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis

Archive ouverte

Bakker, Wineke | Salinas, Casper Gravesen | Imbernon, Monica | Chao, Daniela Herrera Moro | Hassouna, Rim | Morel, Chloe | Martin, Claire | Gangarossa, Giuseppe | Denis, Raphael Gp | Castel, Julien | Peter, Andreas | Heni, Martin | Maetzler, Walter | Nielsen, Heidi Solvang | Duquenne, Manon | Secher, Anna | Hecksher-Sørensen, Jacob | Åskov Pedersen, Thomas | Prevot, Vincent | Luquet, Serge

Edité par CCSD -

The control of body weight and glucose homeostasis are the bedrock of type 2 diabetes medication. Therapies based on co-administration of glucagon-like peptide-1 (GLP-1) long-acting analogues and insulin are becoming popular in the treatment of T2D. Both insulin and GLP-1 receptors (InsR and GLP1-R, respectively) are expressed in brain regions critically involved in the regulation of energy homeostasis, suggesting a possible cooperative action. However, the mechanisms underlying the synergistic action of insulin and GLP-1R agonists on body weight loss and glucose homeostasis remain largely under-investigated. In this study, we provide evidence that peripheral insulin administration modulates the action of GLP-1R agonists onto fatty acids oxidation. Taking advantage of fluorescently labeled insulin and GLP-1R agonists, we found that glucoprivic condition, either achieved by insulin or by 2-deoxyglucose (2-DG), acts as a permissive signal on the blood-brain barrier (BBB) at circumventricular organs, including the median eminence (ME) and the area postrema (AP), enhancing the passage and action of GLP-1-R agonists. Mechanistically, this phenomenon relied on the release of tanycyctic vascular endothelial growth factor A (VEGF-A) and it was selectively impaired after calorie-rich diet exposure. Finally, we found that in human subjects, low blood glucose also correlates with enhanced blood-to-brain passage of insulin suggesting that changes in glycaemia also affect passage of peptide hormones into the brain in humans. . In conclusion, we describe a yet unappreciated mechanism by which acute variations of glycaemia gate the entry and action of circulating energy-related signals in the brain. This phenomenon has physiological and clinical relevance implying that glycemic control is critical to harnessing the full benefit of GLP-1R agonist co-treatment in body weight loss therapy.

Suggestions

Du même auteur

Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis

Archive ouverte | Bakker, Wineke | CCSD

International audience. Therapies based on glucagon-like peptide-1 (GLP-1) long-acting analogs and insulin are often used in the treatment of metabolic diseases. Both insulin and GLP-1 receptors are expressed in met...

Hypothalamic astrocytes control systemic glucose metabolism and energy balance via regulation of extra-synaptic glutamate signaling

Archive ouverte | Chao, Daniela Herrera Moro | CCSD

Summary The hypothalamus is key in the control of energy balance. However, to this day strategies targeting hypothalamic neurons failed to provide viable option to treat most metabolic diseases. Conversely, the role of astrocytes ...

Circulating triglycerides gate dopamine-associated behaviors through DRD2-expressing neurons

Archive ouverte | Berland, Chloé | CCSD

International audience. Energy-dense food alters dopaminergic (DA) transmission in the mesocorticolimbic (MCL) system and can promote reward dysfunctions, compulsive feeding, and weight gain. Yet the mechanisms by w...

Chargement des enrichissements...